Search

Background: International travel can increase the risk of exposure to infectious diseases including sexually transmissible infections (STI). Pre-travel medical consultation provides an opportunity for travel-related health risk assessments and advice. This study explored how travel medicine clinicians integrate sexual and reproductive health (SRH) services into clinical practice. Methods: A convenience sample of travel medicine clinicians completed a cross-sectional survey online or via hard-copy disseminated at an annual national Australian travel medicine conference. Results: Of the 67 respondents, most (n , 51; 76.1%) had a postgraduate qualification relevant to travel medicine and 55.2% (n , 37) had worked in travel medicine for over 10 years. Only 22.4% (n , 15) reported conducting a SRH history/STI risk assessment for all travel patients. STI testing pre-departure was conducted on patient request (48, 71.6%), if symptomatic (32, 47.8%) or based on risk history (28, 41.8%). SRH information pre-departure was most frequently provided if prompted by patient questions (n , 42; 62.7%), or based on the patient's history (n , 37; 55.2%). Over half the sample (n , 40; 59.7%) expressed interest in further training in SRH. Conclusion: Providing and engaging with additional training may assist travel medicine clinicians to take a more proactive approach to SRH consultations and STI testing. Additional research is needed to explore models of care that will allow comprehensive SRH and STI services to be integrated into standard pre- and post-travel care. International travel can increase the risk of exposure to infectious diseases including sexually transmissible infections and human immunodeficiency virus. This study explored how travel medicine clinicians integrate sexual and reproductive health (SRH) services into clinical practice. Our findings highlighted gaps in the provision of pre-travel consultation and training needs for SRH among travel medicine clinicians, and the potential for improved promotion of sexual health among travellers to provide important public health benefits for individuals and the wider community. [ABSTRACT FROM AUTHOR]

Background The wellbeing and safety of international tourists is a paramount concern for governments and stakeholders. Mortality among travellers and the causes of death serve as a significant metric of destination safety. We describe the epidemiology and causes of death among international travellers in Peru. Methods Data retrieved from the Peruvian government's deaths certificates registry included all non-residents who died between January 2017 and December 2021. We analysed the national incidence and causes of death among international travellers in Peru. Causes of death were classified into non-communicable diseases (NCD), communicable diseases and injuries. We classified fatalities according to the existence of preventive measures that could be provided during the travel medicine consultation to decrease the risk. Results We obtained records from 1514 deaths among international travellers (973 males, 64%). The incidence increased from 0.2 deaths per 10 000 travellers in 2017 to 9.9 in 2021. NCDs were the most common causes of death (n  = 560, 37%), followed by communicable diseases (n  = 487, 32%), and injuries (n  = 321, 21%). Causes of death were unknown in 9.7% of the records. The leading causes of death in these categories were cancer, cardiovascular disease, COVID-19 and trauma. We found similar sex distribution of NCDs in travellers aged >50 years and higher rates of communicable diseases among males across all ages. Injury-associated deaths were significantly higher among males aged 18–29 years (P  < 0.001) compared with other sex-age groups. We estimated that for 57.7% of deaths risk could have been decreased through pre-travel advice. Conclusion Rates of deaths among travellers to Peru increased over time. Most deaths were due to NCDs, followed by communicable diseases and injuries. Pre-travel medical optimization and effective advice focused on age-sex and destination specific risks could reduce risk among travellers. Increased awareness among travel medicine practitioners and improvement of emergency medical response systems in Peru could decrease mortality. [ABSTRACT FROM AUTHOR]

This article discusses the use of the Dengvaxia® vaccine in Australian travelers. Dengue fever is a mosquito-borne viral disease that can cause severe complications. Dengvaxia® is a live recombinant tetravalent dengue vaccine that was licensed in Mexico in 2015 and has since been approved in over 20 countries. In Australia, Dengvaxia® is recommended for long-term travelers aged 9-45 years who have had previous dengue infection and plan to reside in highly dengue-endemic regions. However, its use in Australia has been limited due to strict criteria and high cost. A case series of seven travelers who received Dengvaxia® at a travel medicine clinic in Brisbane found that the vaccine was well-tolerated, with only mild to moderate adverse events reported. It is important to note that most travelers from non-endemic countries should not receive Dengvaxia® as they are seronegative and may be at risk of severe dengue. While another dengue vaccine, Qdenga®, is available in some countries, Dengvaxia® remains the only option for Australian travelers at present. The study acknowledges its limitations, including the small sample size and the fact that it represents the experience of one clinic. Overall, Dengvaxia® has been rarely used in Australia but may be considered in certain circumstances. [Extracted from the article]

Campylobacter infection is one of the most frequently reported foodborne diseases with approximately 230,000 and 1.5 million cases each year in Europe and the USA, respectively. Culture methods are the reference for the diagnosis of Campylobacter infections; however, these methods are complex and time-consuming. Multiplex nucleic acid amplification test is favored due to its rapidity, automatization in the procedure followed and the quick simultaneous testing of numerous foodborne pathogens. The aim of this meta-analysis was to evaluate the accuracy of these tests for the diagnosis of Campylobacter infection. Scopus, Science Direct, PubMed, Web of Science, and Mendeley were searched for peer-reviewed articles. The split component synthesis method with the use of the inverse variance heterogeneity model was chosen for the quantitative meta-analysis. Sensitivity analysis was performed by age category and index test. The literature search found 34 studies involving 28,105 patients with suspected gastroenteritis. The sensitivity and specificity were 95.3% (92.3; 97.1) and 97.1% (95.1; 98.3), respectively, and AUC (area under the curve) was 0.963 (0.947; 0.974). Pediatric patients had a lower sensitivity (87.4, 48.2; 98.1) and higher specificity (99.2, 91.6; 99.9) estimate compared to all ages category (sensitivity 95.3, 91.3; 97.5, specificity 96.7, 93.7; 98.3). Among the various index tests, Seeplex/Allplex and Amplidiag/Novodiag had the lowest estimate for sensitivity (88.9, 73.8; 95.8) and specificity (95.2, 86; 98.4), respectively. BDMax had the highest (sensitivity 98.1, 96.1; 99 and specificity 98.5, 97; 99.3). Multiplex nucleic acid tests showed excellent accuracy and could play an influential role in diagnosing Campylobacter infections. [ABSTRACT FROM AUTHOR]

Infection of the respiratory tract with an influenza virus results in symptoms ranging from mild nonfebrile illness to severe disease and complications, including pneumonia, shock, renal failure, encephalopathy, and multiorgan [...]